Table 1.

Effects of oral gavage administration of favipiravir and oseltamivir, either alone or in combination, on the survival of mice inoculated with pandemic influenza A/California/04/2009 (H1N1pdm) virus.

Compound (mg/kg/day)	Oseltamivir (3)	Oseltamivir (1)	Oseltamivir (0.3)	Oseltamivir (0.1)	Oseltamivir (0)
Favipiravir (30)	10/10*** (>21)	6/10** (9.3 ± 2.6)	4/10* (7.8 ± 1.2)	4/10* (8.0 ± 0.9)	1/10 (7.4 ± 1.3)
Favipiravir (10)	9/10*** (9.0)	3/10* (8.4 ± 1.3)	2/10 (8.1 ± 1.9)	1/10 (7.8 ± 0.8)	0/10 (6.9 ± 0.9)
Favipiravir (3)	8/10*** (9.5 ± 2.1)	3/10* (9.7 ± 2.0)	2/9 (8.9 ± 2.5)	1/10 (8.0 ± 1.1)	0/10 (8.0 ± 1.6)
Favipiravir (1)	7/10*** (8.7 ± 1.2)	3/10* (8.4 ± 1.7)	4/10* (6.7 ± 1.2)	1/10 (7.6 ± 1.1)	0/10 (6.7 ± 1.1)
Favipiravir (0)	5/10** (7.8 ± 0.8)	4/10* (7.2 ± 0.8)	4/10* (7.2 ± 1.3)	1/10 (7.0 ± 0.9)	1/20 (6.5 ± 0.6)

Results are demonstrated as survivors/total (mean day of death of mice that died during the 21-day observation period ± standard deviation). The mean day of death test is statistically analyzed only for mice that die. Mean without standard deviation data means only one mouse died. >21 indicates that all of the mice lived through the end of the experiment.

^*p < 0.05;

^**p < 0.01;

^***p < 0.001, compared with placebo.